EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease

Dinesh Khanna iD, Luke B Evnin, Shervin Assassi iD, Wade W Benton, Gregory Gordon, Karina Maslova, Juergen Steffgen, Toby M Maher

Journal of Scleroderma and Related Disorders · 2025-06 · 10 (2) · 121-132

DOI: 10.1177/23971983241278079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Scleroderma and Related Disorders, online erschienen am 05.11.2024. Verfasst von Dinesh Khanna und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Safe, effective therapies are urgently needed for patients with systemic sclerosis. However, clinical trial recruitment is challenging given the limited number of people with systemic sclerosis and further restrictions imposed by eligibility criteria. Innovative approaches are needed to accelerate development of new therapies. This article describes the rationale and trial design for CONQUEST (NCT06195072), a novel platform clinical trial sponsored by the Scleroderma Research Foundation, a not-for-profit organization.

Methods

CONQUEST is a multicentre, double-blind, randomized, placebo-controlled, Phase 2b platform trial evaluating the efficacy, safety and pharmacodynamics of multiple investigational products to treat early active systemic sclerosis with interstitial lung disease versus placebo. The primary objective is to evaluate change from baseline to Week 52 in forced vital capacity (mL). Secondary objectives include evaluating changes from baseline to Week 52 in high-resolution computed-tomography-assessed lung involvement and dyspnoea, and overall treatment response (measured using the revised composite response index in diffuse systemic sclerosis score in participants with diffuse cutaneous systemic sclerosis).

Results

Patients will be enrolled across more than 150 centres in over 25 countries. Recruitment started on 15 April 2024.

Conclusion

As the first platform clinical trial in the rheumatology field, CONQUEST aims to meaningfully accelerate the development of new therapies for early active systemic sclerosis. Depending on regimen-specific results, trial data could be used to plan and design a Phase 3 trial or may be used alone or together with another registrational trial to establish substantial evidence of effectiveness and safety. The first molecules to be studied, amlitelimab and nerandomilast, both have a strong scientific rationale to modify underlying disease processes in systemic sclerosis. ClinicalTrials.gov: Platform Clinical Study for Conquering Scleroderma (CONQUEST); NCT06195072; https://www.clinicaltrials.gov/study/NCT06195072

Schlagwörter

Stichwörter der Autor:innen

Systemic sclerosisamlitelimabinterstitial lung diseasenerandomilastplatform trialrandomized clinical trialsclerodermastudy design

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Scleroderma Research Foundation, San Francisco, CA, USA.
  • Division of Rheumatology, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Eicos Sciences, San Mateo, CA, USA.
  • Sanofi, Cambridge, MA, USA.
  • Therapeutic Area Inflammation Medicine, Boehringer Ingelheim International GmbH, Biberach, Germany.

ORCID-Profile: Dinesh Khanna, Shervin Assassi

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Khanna, D., Evnin, L. B., Assassi, S., Benton, W. W., Gordon, G., Maslova, K., Steffgen, J., & Maher, T. M. (2025). Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease. Journal of Scleroderma and Related Disorders, 10(2), 121-132. https://doi.org/10.1177/23971983241278079

Vancouver

Khanna D, Evnin LB, Assassi S, Benton WW, Gordon G, Maslova K, et al. Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease. Journal of Scleroderma and Related Disorders. 2025;10(2):121-132. doi:10.1177/23971983241278079

BibTeX
@article{Khanna2025,
  author = {Khanna, Dinesh and Evnin, Luke B and Assassi, Shervin and Benton, Wade W and Gordon, Gregory and Maslova, Karina and Steffgen, Juergen and Maher, Toby M},
  title = {Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease},
  journal = {Journal of Scleroderma and Related Disorders},
  year = {2025},
  volume = {10},
  number = {2},
  pages = {121--132},
  doi = {10.1177/23971983241278079}
}
Kostenlos starten →